Wayne Kuznar | Authors

June 09, 2022

Benefit across a range of survival end points, including progression-free survival, shown with tislelizumab and chemotherapy for patients with recurrent or metastatic nasopharyngeal carcinoma.

June 08, 2022

In CPI-naïve, HPV16-positive, CPS-positive patients, PDS0101 plus pembrolizumab exhibits preliminary evidence of clinical benefit in a majority of patients with an acceptable safety profile and allows continued dosing of pembrolizumab.

June 08, 2022

The addition of zanubrutinib to obinutuzumab in patients with relapsed/refractory follicular lymphoma demonstrated improved overall response rates, progression-free survival, and overall survival.

June 08, 2022

According to Eric Bouffet, MD, results from a phase 2 study presented during the 2022 ASCO Annual Meeting show how important it is to document as early as possible the molecular alterations that are present in this type of tumor.

June 06, 2022

Dafrafenib plus trametinib demonstrated greatly improved response rates and progression-free survival in pediatric patients with BRAF V600-mutated gliomas.

June 06, 2022

According to Grzegorz S. Nowakowski, MD, results from a subgroup analysis of the observational RE-MIND study may aid in contextualizing therapy options for treating patients with relapsed or refractory diffuse large B-cell lymphoma.